Bicara Therapeutics (BCAX) Current Assets (2023 - 2026)
Bicara Therapeutics (BCAX) posted quarterly Current Assets of $544.9 million for Q1 2026, up 15.75% year-over-year from $470.8 million in Q1 2025, and up 29.11% quarter-over-quarter from $422.1 million in Q4 2025.
Bicara Therapeutics (BCAX) Current Assets (2023 - 2026) Analysis & Trends
Bicara Therapeutics' Current Assets history runs 4 years deep, the most recent figure standing at $544.9 million for Q1 2026.
- In Q1 2026, Current Assets rose 15.75% year-over-year to $544.9 million; the TTM figure through Mar 2026 stood at $544.9 million (up 15.75% YoY), while the FY2025 annual figure was $422.1 million, down 16.01% from the prior year.
- Current Assets for Q1 2026 stood at $544.9 million, up from $422.1 million in the prior quarter.
- The five-year high for Current Assets was $544.9 million in Q1 2026, with the low at $231.1 million in Q4 2023.
- The 4-year median for Current Assets is $457.6 million (2025), against an average of $429.3 million.
- The sharpest annual moves came in 2024 and 2025: Current Assets surged 117.48% in 2024, then sank 42.98% in 2025.
- Bicara Therapeutics' Current Assets stood at $231.1 million in 2023, then soared by 117.48% to $502.5 million in 2024, then retreated by 16.01% to $422.1 million in 2025, then advanced by 29.11% to $544.9 million in 2026.
- Business Quant data shows BCAX's Current Assets at $544.9 million in Q1 2026, $422.1 million in Q4 2025, and $297.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Bicara Therapeutics | 1.60 Bn | 1.60 Bn | - | 503.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 503.82 Mn |
| Mar 31, 2026 | 544.92 Mn |
| Dec 31, 2025 | 422.05 Mn |
| Sep 30, 2025 | 297.37 Mn |
| Jun 30, 2025 | 444.39 Mn |
| Mar 31, 2025 | 470.75 Mn |
| Dec 31, 2024 | 502.53 Mn |
| Sep 30, 2024 | 521.51 Mn |
| Dec 31, 2023 | 231.07 Mn |